Aptose Biosciences Inc.
NASDAQ:APTO
0.25 (USD) • At close December 24, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Aptose Biosciences Inc. |
Symbool | APTO |
Munteenheid | USD |
Prijs | 0.25 |
Beurswaarde | 14,880,300 |
Dividendpercentage | 0% |
52-weken bereik | 0.13 - 2.68 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. William G. Rice Ph.D. |
Website | https://www.aptose.com |
An error occurred while fetching data.
Over Aptose Biosciences Inc.
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)